DK160190D0 - Neurit-vaekstregulerende faktorer - Google Patents

Neurit-vaekstregulerende faktorer

Info

Publication number
DK160190D0
DK160190D0 DK160190A DK160190A DK160190D0 DK 160190 D0 DK160190 D0 DK 160190D0 DK 160190 A DK160190 A DK 160190A DK 160190 A DK160190 A DK 160190A DK 160190 D0 DK160190 D0 DK 160190D0
Authority
DK
Denmark
Prior art keywords
proteins
metalloproteases
present
neurit
inhibitors
Prior art date
Application number
DK160190A
Other languages
English (en)
Other versions
DK160190A (da
Inventor
Martin E Schwab
Pierenrico W Caroni
Paolo A Paganetti
Original Assignee
Zuerich Erziehungsdirektion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/401,212 external-priority patent/US5684133A/en
Application filed by Zuerich Erziehungsdirektion filed Critical Zuerich Erziehungsdirektion
Publication of DK160190D0 publication Critical patent/DK160190D0/da
Publication of DK160190A publication Critical patent/DK160190A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/06—Chelate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
DK160190A 1988-11-04 1990-07-03 Neurit-vaekstregulerende faktorer DK160190A (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26794188A 1988-11-04 1988-11-04
US07/401,212 US5684133A (en) 1988-11-04 1989-08-30 Neurite growth regulatory factors, antibodies thereto, and pharmaceutical compositions
PCT/EP1989/001321 WO1990005191A1 (en) 1988-11-04 1989-11-02 Neurite growth regulatory factors

Publications (2)

Publication Number Publication Date
DK160190D0 true DK160190D0 (da) 1990-07-03
DK160190A DK160190A (da) 1990-09-03

Family

ID=26952762

Family Applications (1)

Application Number Title Priority Date Filing Date
DK160190A DK160190A (da) 1988-11-04 1990-07-03 Neurit-vaekstregulerende faktorer

Country Status (8)

Country Link
US (2) US6025333A (da)
EP (1) EP0396719B1 (da)
KR (1) KR100196540B1 (da)
AT (1) ATE124726T1 (da)
AU (2) AU652537B2 (da)
DE (1) DE68923362T2 (da)
DK (1) DK160190A (da)
WO (1) WO1990005191A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005191A1 (en) * 1988-11-04 1990-05-17 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
WO1993000427A2 (en) * 1991-06-24 1993-01-07 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
US7226758B1 (en) * 1991-09-20 2007-06-05 Amgen Inc. Nucleic acids encoding glial cell line-derived neurotrophic factor (GDNF)
WO1994017831A1 (en) * 1993-02-11 1994-08-18 Erziehungsdirektion Of The Canton Zurich A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
US6576607B1 (en) 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
PL322947A1 (en) * 1995-04-19 1998-03-02 Acorda Therapeutics Growth modulators capable to modulate growth of central nervous system axones as well as compositiona and cells for and method of obtaining und using them
EP0896058B1 (en) 1995-12-06 2009-02-25 Dainippon Sumitomo Pharma Co., Ltd. Novel semaphorin z and gene encoding the same
AU4136797A (en) 1996-09-11 1998-04-02 Sumitomo Pharmaceuticals Company, Limited Novel semaphorin gene: semaphorin y
WO1998015628A1 (fr) 1996-10-09 1998-04-16 Sumitomo Pharmaceuticals Company, Limited Nouveau gene de semaphorine: la semaphorine w
CA2271681A1 (en) 1996-11-15 1998-05-28 Sumitomo Pharmaceuticals Co., Ltd. Novel semaphorin genes (i)
JP2002518010A (ja) 1998-06-16 2002-06-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９４個のヒト分泌タンパク質
IL142989A0 (en) 1998-11-06 2002-04-21 Nucleotide and protein sequences of nogo genes and methods based thereon
EP2163561A1 (en) 2000-01-12 2010-03-17 Yale University NOGO receptor-mediated blockade of axonal growth
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
CA2424834A1 (en) * 2000-10-06 2002-04-11 Yale University Nogo receptor homologs
EP1805209A4 (en) * 2004-10-01 2008-04-02 Univ Yale NOGO-A POLYPEPTIDE FRAGMENTS, VARIANT OF NOGO RECEPTOR-1 POLYPEPTIDES AND USE
US20060217324A1 (en) * 2005-01-24 2006-09-28 Juergen Soutschek RNAi modulation of the Nogo-L or Nogo-R gene and uses thereof
US7893032B2 (en) * 2005-07-07 2011-02-22 Yale University NgR variants and compositions thereof for suppressing axonal growth inhibition
US7772200B2 (en) * 2005-07-21 2010-08-10 Alnylam Pharmaceuticals, Inc. iRNA agents targeted to the Rho-A gene
AU2006282856A1 (en) * 2005-08-25 2007-03-01 Biogen Idec Ma Inc. Nogo receptor polypeptides and polypeptide fragments and uses thereof
KR100756423B1 (ko) 2005-10-27 2007-09-07 한국과학기술연구원 성선자극호르몬 수용체를 바이오마커로 이용한 마이엘린의탐색방법
KR20080073748A (ko) * 2005-11-16 2008-08-11 노파르티스 아게 척수 손상에서의 항-ｎｏｇｏ-ａ 항체 치료를 위한바이오마커
EP2023735A4 (en) * 2006-05-15 2011-05-25 Biogen Idec Inc USE OF ANTAGONISTS OF THE NOGO RECEPTOR 1 (NGR1) TO PROMOTE THE SURVIVAL OF OLIGODENDROCYTES
CN105111310B (zh) 2006-11-21 2019-07-26 雅培制药有限公司 抗nogo-66受体(ngr)的中和单克隆抗体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287184A (en) * 1977-11-23 1981-09-01 The Massachusetts General Hospital Process for healing wounds
US4407744A (en) * 1977-11-23 1983-10-04 Young David M Process for obtaining nerve growth factor
US4230691A (en) * 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
CA1173823A (en) * 1980-08-26 1984-09-04 Leonard M. Hjelmeland Nondenaturing zwitterionic detergent for membrane biochemistry
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
EP0155433A1 (en) * 1984-03-23 1985-09-25 Adriano Fontana Immunosuppressant factor
CA1341401C (en) * 1984-03-23 2002-11-26 Adriano Fontana Immunosuppressant factor derived from human glioblastoma cells
US4803163A (en) * 1984-06-04 1989-02-07 E. I. Du Pont De Nemours And Company Preparation of a protein fraction exhibiting cell growth-inhibiting activity
EP0233838A3 (en) * 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
WO1990005191A1 (en) * 1988-11-04 1990-05-17 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors

Also Published As

Publication number Publication date
AU680932B2 (en) 1997-08-14
KR100196540B1 (ko) 1999-06-15
AU4528089A (en) 1990-05-28
WO1990005191A1 (en) 1990-05-17
KR900702050A (ko) 1990-12-05
AU7435494A (en) 1994-12-15
DE68923362T2 (de) 1996-03-28
ATE124726T1 (de) 1995-07-15
DE68923362D1 (de) 1995-08-10
DK160190A (da) 1990-09-03
US6103232A (en) 2000-08-15
EP0396719A1 (en) 1990-11-14
AU652537B2 (en) 1994-09-01
EP0396719B1 (en) 1995-07-05
US6025333A (en) 2000-02-15

Similar Documents

Publication Publication Date Title
DK160190D0 (da) Neurit-vaekstregulerende faktorer
GR3033103T3 (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
ATE323482T1 (de) Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
DE69429721D1 (de) Verwendung von neuronalen fötalen zellinien für transplantationstherapie
ES2149888T3 (es) 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
ATE281840T1 (de) Behandlung von diarrhoe
MX9604985A (es) Cardiotropina y usos de la misma.
ATE288490T1 (de) Neue menschliche cdc25 gene, kodierte produkte und ihre verwendung
DE69733968D1 (de) Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen
DE69403969D1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
DE59310327D1 (de) Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
WO1993000427A3 (en) Neurite growth regulatory factors
DE69616792D1 (de) Verwendung von lemellarin alkaloiden in therapeutischen verfahren
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
GB9607249D0 (en) Compounds
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
ATE80998T1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
ES8105392A1 (es) Procedimiento de obtencion de una solucion de aminoacidos y peptidos de origen animal por proceso enzimatico
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus

Legal Events

Date Code Title Description
A0 Application filed
AHB Application shelved due to non-payment
PBP Patent lapsed